samedan logo
home > pmps > autumn 2019 > the roi of real-time supply chain visibility
Pharmaceutical Manufacturing and Packing Sourcer

The ROI of Real-Time Supply Chain Visibility

In the life sciences supply chain, maintaining strict temperature conditions to ensure consistent product quality and integrity remains a key challenge for enterprises. As the global cold chain grows in complexity, there is an increasing need to capture environmental and product movement traceability data in real time to reduce product and operational waste, satisfy the reporting requirements, and share data with key stakeholders. Too often, supply chain data is siloed, preventing mission-critical information from driving both day-to-day and strategic decisions.

Approximately $53 billion worth of global biopharma products are at risk of temperature excursions every year. Supply chain transparency, collaboration, and resilience are becoming increasingly important because the frequency, magnitude, and costs of disruptions are increasing. This trend is expected to continue.

Multiple Risk Points

Within the cold chain, problems typically happen at multiple handoff points. Today, temperature excursions account for nearly 80% of supply chain problems. Each lane of travel – air, road, rail, and sea – requires different types of handoff points and poses different risks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Controlant's mission is to ensure consumer safety and decrease waste by digitally connecting the end-to-end supply chain. The pay-per-shipment, ChaaS solution provides a single source of supply chain truth, consisting of reusable IoT data loggers that send mission-critical data and insights in realtime to a proprietary, cloud-enabled software platform, and cost-reducing operational services. Controlant customers leverage the improved visibility to connect stakeholders, improve efficiency, and increase revenues.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine.
More info >>

White Papers

New Temperature Profiles from a Global Study

Laminar Medica

Recently there has been an influx of temperature mapping studies to collect sufficient ambient data to develop temperature profiles.  Solid temperature profiles on specific shipping routes are required to ensure streamlined packaging and robust lane qualification. The most reliable method to develop temperature profiles is to capture the actual reading from shipments, as well as using the historical and meteorological data to increase the confidence level.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement